Stephens analyst Sudan Loganathan initiated coverage of Bicycle Therapeutics (BCYC) with an Equal Weight rating and $25 price target as the firm is adding to its biotechnology research coverage with a focus on antibody-drug delivery technologies for the treatment of cancers. Bicycle has a proven platform of novel precision guided medicines to target cancers, but its lead assets have an “uphill battle to compete with incumbents,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Faces Strategic Risks from Concentrated Shareholder Influence
- Bicycle Therapeutics: Promising Q3 Results and Business Progress
- Bicycle Therapeutics reports Q3 EPS (74c), consensus (78c)
- BCYC Earnings this Week: How Will it Perform?
- Bicycle Therapeutics announces presentation of MT1-MMP data